Medtronic/MiniMed Insulin Pump Paradigm Aims To Grow 80% Market Share
This article was originally published in The Gray Sheet
Executive Summary
Medtronic/MiniMed expects to boost its 80% share of the U.S. diabetes pump market with the Paradigm Model 511 insulin infusion system. A full-scale U.S. launch was announced Feb. 18
You may also be interested in...
Medtronic Artificial Pancreas Sustains Normal Glucose 42% Of The Time
Medtronic/MiniMed continues to predict that its artificial pancreas technology will reach the U.S. market in five years, based on early-stage data showing the system maintains glucose levels in the near-normal range 42% of the time
Medtronic Artificial Pancreas Sustains Normal Glucose 42% Of The Time
Medtronic/MiniMed continues to predict that its artificial pancreas technology will reach the U.S. market in five years, based on early-stage data showing the system maintains glucose levels in the near-normal range 42% of the time
Medtronic Seals FDA Panel Endorsement With InFuse Bone Growth Product
Preclinical studies of the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on tumorogenicity, dosing and antibody response during pregnancy should be conducted by Medtronic/Sofamor Danek, FDA's Orthopedic & Rehabilitation Devices Panel recommended Jan. 10